SINGAPORE, July 22,
2024 /PRNewswire/ -- QDX, a computational drug
discovery company, today announced
a collaboration with Prelude Therapeutics, a clinical-stage
precision oncology company, targeting undisclosed, previously
undrugged oncology targets.
QDX integrates its world-leading quantum mechanical simulation
technology, supercomputing, artificial intelligence, and deep drug
discovery expertise to advance computational chemistry and drug
discovery.
Peggy Scherle, PhD, CSO of
Prelude, commented: "Computational approaches to drug discovery are
showing increasing promise. We are pleased to work with the
talented team at QDX to leverage their blend of high-performance
computing, quantum simulations, and AI on these historically
challenging targets."
Loong Wang, Co-Founder and CEO of
QDX, stated: "We are thrilled to be working with the team at
Prelude to help break new ground on these programs. This
collaboration with Prelude exemplifies the kind of bespoke
partnerships that QDX engages in across academia and industry,
deploying our best-in-class quantum technology, our massively
parallel supercomputing, and AI systems."
Kelvin Neu, MD, Co-Founder and
Chair of QDX, added: "The accomplished biology and chemistry teams
at Prelude have been very productive, generating a pipeline of
small molecules against important and often challenging oncology
targets. QDX has built a powerful platform by thoughtfully
integrating complementary disciplines, guided by the practical
needs and challenges of novel drug discovery, with a particular
focus on select traditionally difficult-to-crack areas. We are
honored that Prelude has chosen QDX to support them on these
challenging targets and look forward to a productive
collaboration."
About QDX
QDX is a computational drug discovery company integrating
quantum mechanical simulations, supercomputing, and artificial
intelligence. By developing new systems and algorithms from ground
up and optimizing existing software for modern hardware, QDX
achieves large-scale molecular dynamics and quantum simulations
with unmatched speed and scale. From small molecules to entire
protein complexes, QDX makes quantum simulations pragmatic and
relevant in applications such as drug discovery and materials
science.
QDX's cross-disciplinary team focuses on industrializing,
specializing, and delivering on the promise of classical and
quantum computational chemistry for a range of applications and
industries. Initially focusing on drug discovery, QDX collaborates
with researchers and companies on complex projects, providing
unique insights and capabilities through large-scale computations,
quantum simulations, proprietary high-quality quantum training
data, AI, and custom software. QDX is a globally-minded company
based in Singapore and
Australia. For more information
please visit www.qdx.co.
View original
content:https://www.prnewswire.com/news-releases/qdx-announces-collaboration-with-prelude-therapeutics-on-novel-oncology-programs-302202323.html
SOURCE QDX